• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
CCAIM

CCAIM

Novel AI to transform healthcare

  • Home
  • About
    • Our Aims
    • ISAB Report
  • People
    • Leadership
    • Faculty
    • Associate Faculty
    • Joint Steering Committee
    • Independent Scientific Advisory Board
    • Staff
    • Our students
    • Affiliated clinical PhD Students
    • Visitors
  • Research
    • Papers
    • Breakthroughs
    • Software
      • AutoPrognosis
      • HyperImpute
      • Interpretability Suite
      • Synthcity
      • TemporAI
    • Demonstrators
    • Research Update: COVID-19
    • Blog
  • News
    • Latest News
    • COVID-19 News
  • Events
    • Seminar Series
    • WeCREATE
    • Inaugural Event
    • AI Clinic 2023
    • AI Clinic 2022
  • Summer School
    • Summer School 2023
      • Participate
      • Program
      • Topics
      • Industry
      • FAQ
    • Summer School 2022
  • Get involved
    • PhD Programmes
    • Clinical PhD Position
    • Partners
    • Connect

Biomedical discovery

Scientists are currently hampered in the discovery of optimal drug targets by a failure to understand biological processes at a systems level.

PAPERS
BREAKTHROUGHS

CCAIM’s first aim in the biomedical arena is to leverage structural, metabolic and genetic metadata to develop multiscale generative models – at the level of molecules, cells, organs and whole organisms – to uncover novel targets for antibiotics and host-directed therapies, and define new approaches to modulate inflammation and immunity.

We will also develop new, interpretable deep learning methods to better predict the functional impacts of the protein mutations seen in antimicrobial resistance and cancer using structural modelling, and develop in silico screening methods that better ascertain feature weights and interactions. Crucially, these methods will explicitly state the confidence of machine-learning (ML) predictions.

Finally, we will create new ML/AI methods in cheminformatics to define the boundary conditions for the drug-like chemical space, initially focusing on predicting adequate bacterial permeability to support structure-guided antibiotic development.

Sometimes, however, the scientific agenda is set by world events, and CCAIM was swift to tailor its biomedical discovery approaches to help tackle the COVID-19 pandemic.  

Targeting COVID-19

A team led by CCAIM Co-Director, Andres Floto, a Professor of Respiratory Biology at the University of Cambridge, is exploring a combination of structural and dynamic modelling approaches to predict new drug targets against SARS-CoV-2, the virus that causes COVID-19.  This methodology involves the analysis of a metabolic model that integrates the cell metabolism of various cells of humans infected with coronavirus. The model is providing an in silico comparison of the biochemical demands of the virus versus the infected host cells, and expanding the model to predict the effect of various treatment regimens for COVID-19, looking for- the best drug-optimisation strategies against the virus.

The more we can learn about the fundamental biology and interactions of SARS-CoV-2, the more powerful this sort of drug discovery work becomes. This brings us to CCAIM team member Dr Sarah Teichmann, and her colleagues at the Wellcome Sanger Institute and Human Cell Atlas (HCA) Lung Biological Network.

To explore which of the body’s cells could be involved in the transmission of COVID-19, these researchers analysed multiple datasets of single-cell RNA sequencing, from a variety of tissues from healthy people, including cells from the lung, nasal cavity, eye, gut, heart, liver and kidney. This research, published in Nature on 23 April 2020, looked for individual cells that expressed both of two key proteins that the virus attaches to when infecting our cells – ACE2 and TMPRSS2. They discovered that two types of cells in the nose have particularly high levels of these, making them likely points of entry for COVID-19. This sort of science is foundational to developing medical responses to the pandemic.

Discover more about CCAIM’s wider response to COVID-19. 

Sidebar

Unable to load Tweets

Follow

Recent Posts

  • Prof Mihaela van der Schaar joining panel on oncology at ASCO2023
  • Learning Representations without Compositional Assumptions
  • Revolutionising Pharmacological Predictions: How Synthetic Model Combination (SMC) Could Change the Game for Drug Development
  • CCAIM at ICML 2023: 12 papers from our faculty
  • Staff

Navigation

Home

News

About

University of Cambridge

  • University A-Z
  • Contact the University
  • Accessibility
  • Data Protection
  • Terms and conditions

Newsletter

Sign-up for updates on our research.

Follow us

  • Twitter
  • LinkedIn
  • YouTube

Copyright © 2023 CCAIM

Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

CCAIM
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!